| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |